美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Adarx Pharmaceuticals, inc

17.66

-0.3100-1.73%

成交量：9.61万

成交额：172.88万

市值：18.05亿

市盈率：-2.28

高：18.82

开：18.00

低：17.57

收：17.97

52周最高：23.21

52周最低：16.64

股本：1.02亿

流通股本：1.02亿

量比：0.20

换手率：0.09%

股息：- -

股息率：- -

每股收益(TTM):-7.7403

每股收益(LYR):-6.4321

净资产收益率：-38.89%

总资产收益率：-14.90%

市净率：-7.19

市盈率(LYR):-2.75

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Adarx Pharmaceuticals, inc

交易所：

NASDAQ

成立时间：

2019

员工人数：

100

公司地址：

5871 Oberlin Drive,Suite 200,San Diego,California,United States

官网：

http://www.adarx.com

邮编：

92121

电话：

传真：

- -

简介：

ADARx Pharmaceuticals, Inc.于2019年12月在特拉华州注册成立。该公司是一家临床后期阶段的生物技术公司，专注于开发旨在治疗广谱疾病的下一代siRNA疗法，推进一系列高效、选择性和持久的siRNA治疗候选药物，包括三个临床阶段项目和两个先进的临床前项目。

董事

名称

职位

Erez Chimovits

Director and Interim Chairman of the Board

Zhen Li

Chief Executive Officer and Director and President

Carl L. Gordon

Director

Chen Yu

Director

Judith J. Li

Director

Mary Tagliaferri

Director

Ricky Sun

Director

Simeon George

Director

Ting Feng

Director

Ying Huang

Director

股东

名称

职位

Zhen Li

Chief Executive Officer and Director and President

Ryan Fisk

Chief Business Officer and Chief Financial Officer

A. Robert MacLeod

Chief Scientific Officer

Robert Ackles

Chief People Officer

Rui Zhu

Chief Technology Officer

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/ADRX/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADRX\",,,,,undefined,":{"symbol":"ADRX","market":"US","secType":"STK","nameCN":"Adarx Pharmaceuticals, inc","latestPrice":17.66,"timestamp":1791915330925,"preClose":17.97,"halted":0,"volume":96129,"delay":0,"changeRate":-0.017250973845297647,"floatShares":102200905,"shares":102200905,"eps":-7.740306,"marketStatus":"交易中","change":-0.31,"latestTime":"10-13 14:15:49 EDT","open":18,"high":18.815,"low":17.57,"amount":1728769.5166500001,"amplitude":0.069282,"askPrice":17.87,"askSize":170,"bidPrice":17.65,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-7.740306,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":2,"adr":0,"listingDate":1790308800000,"exchange":"NASDAQ","adjPreClose":17.97,"preHourTrading":{"tag":"盘前","latestPrice":17.53,"preClose":17.97,"latestTime":"09:29 EDT","volume":368,"amount":6447.075903999999,"timestamp":1791898140519,"change":-0.44,"changeRate":-0.024485,"amplitude":0.11906},"postHourTrading":{"tag":"盘后","latestPrice":17.86,"preClose":17.97,"latestTime":"19:30 EDT","volume":14575,"amount":261884.443,"timestamp":1791847803605,"change":-0.11,"changeRate":-0.006121,"amplitude":0.006121},"volumeRatio":0.204817},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADRX\",,,,,undefined,":{"symbol":"ADRX","floatShares":102200905,"roa":"-14.90%","roe":"-38.89%","lyrEps":-6.432121,"volumeRatio":0.204817,"shares":102200905,"dividePrice":0,"high":18.815,"amplitude":0.069282,"preClose":17.97,"low":17.57,"week52Low":16.6393,"pbRate":"-7.19","psRate":"294.58","week52High":23.21,"institutionHeld":0,"latestPrice":17.66,"committee":-0.259259,"eps":-7.740306,"divideRate":0,"volume":96129,"delay":0,"ttmEps":-7.740306,"open":18,"prevYearClose":17,"prevWeekClose":17.78,"prevMonthClose":19.94,"prevQuarterClose":19.94,"fiveDayClose":18.58,"twentyDayClose":17,"sixtyDayClose":17},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADRX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ADRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ADRX","date":"2026-10-12","current":-2.281564,"percent":0.8,"low":-25.428632,"twenty":-24.918529,"median":-23.694282,"eighty":-22.674076,"high":-22.100211,"avg":-23.808304,"sd":1.057918,"marketCap":1992371095},"quantilePoints":[{"date":"2026-10-02","current":-24.918529,"twenty":-25.150325,"median":-24.918529,"eighty":-24.228516,"marketCap":2189591181},{"date":"2026-10-09","current":-22.540174,"twenty":-24.950973,"median":-23.993968,"eighty":-23.126792,"marketCap":1980605124},{"date":"2026-10-12","current":-22.674076,"twenty":-24.918529,"median":-23.694282,"eighty":-22.674076,"marketCap":1992371095}],"updateTime":1791915349378},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":653770897,"yearFounded":2019,"employeeNum":100,"address":"5871 Oberlin Drive,Suite 200,San Diego,California,United States","zipCode":"92121","officePhone":"(877) 232-7974","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.adarx.com","stockEarnings":[{"period":"1week","weight":-0.0567},{"period":"1month","weight":0.0571},{"period":"ytd","weight":0.0571}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0181},{"period":"3month","weight":0.0349},{"period":"6month","weight":0.1117},{"period":"1year","weight":0.1915},{"period":"ytd","weight":0.141}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ADARx Pharmaceuticals, Inc.于2019年12月在特拉华州注册成立。该公司是一家临床后期阶段的生物技术公司，专注于开发旨在治疗广谱疾病的下一代siRNA疗法，推进一系列高效、选择性和持久的siRNA治疗候选药物，包括三个临床阶段项目和两个先进的临床前项目。","exchange":"NASDAQ","name":"Adarx Pharmaceuticals, inc","nameEN":"ADARx Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ADRX\",market:\"US\",,,undefined,":{"directors":[{"name":"Erez Chimovits","position":"Director and Interim Chairman of the Board"},{"name":"Zhen Li","position":"Chief Executive Officer and Director and President"},{"name":"Carl L. Gordon","position":"Director"},{"name":"Chen Yu","position":"Director"},{"name":"Judith J. Li","position":"Director"},{"name":"Mary Tagliaferri","position":"Director"},{"name":"Ricky Sun","position":"Director"},{"name":"Simeon George","position":"Director"},{"name":"Ting Feng","position":"Director"},{"name":"Ying Huang","position":"Director"}],"executives":[{"name":"Zhen Li","position":"Chief Executive Officer and Director and President"},{"name":"Ryan Fisk","position":"Chief Business Officer and Chief Financial Officer"},{"name":"A. Robert MacLeod","position":"Chief Scientific Officer"},{"name":"Robert Ackles","position":"Chief People Officer"},{"name":"Rui Zhu","position":"Chief Technology Officer"}]}}}